
Curriculum Vitae

NAME HAGEGE ALBERT ALAIN		POSITION TITLE Professor of Cardiology, Paris Descartes University, & Head, Cardiology Department, Hôpital Européen G Pompidou, Paris, France	
EDUCATION/TRAINING			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Paris Descartes University	MD	1986	Medicine, Cardiology
Paris Necker Medical School	MSc	1993	Echocardiography
Paris Descartes University	Research Director	1996	Imaging & Heart Failure
Paris Descartes University	PhD	1999	Cell therapy in Cardiology

A. Positions and Honors

Positions and employments

- Medical residency, Assistance Publique Hôpitaux de Paris (AP/HP) (1980-86)
- Research Fellow, Harvard Medical School & Mass. General Hospital, Boston, USA (1986-88)
- Senior fellow, AP/HP, and Instructor in Cardiology, Paris Descartes University (1988-92)
- Full staff physician, Cardiology Department, Hôpital Européen Georges Pompidou, Paris (1992-2000)
- Director of Research “Ecole Doctorale Biologie-Biotechnologie ” Paris VII University (1995-)
- Member INSERM EMI-0016, Necker Faculty of Medicine, Paris (1997-2004)
- Member INSERM Unit 633, Paris Descartes University, Paris (2004-)
- Professor (1st class) (2001-) & Head (2011), Cardiology Department, Hôp. Européen G. Pompidou, Paris

Other experiences and professional memberships

- Member, INSERM 4902010 & 4R009B Networks (1993-98) and of the European BIOMED I Network (genetics of cardiomyopathies) (1994-96)
- Harvard Alumni Medical Association and Paul Dudley White Society, Cambridge, USA (1888-ongoing)
- Expert for Medical Imaging, French Ministry of Health & AP/HP (1992-1996)
- Member of the scientific council of the “Association Française contre les Myopathies” (AFM) (1996-2000) and Member (2008-2010) & President (2011-) of the Cardiovascular Diseases Committee of the “Fondation de France”, Member of the scientific council of the Fondation “Maladies rares” (2012-)
- Fellow (FESC) (1993-) & Member of the Credential Committee (2011-) of the European Society of Cardiology
- Fellow of the American College of Cardiology (FACC) (2011-)
- Vice-President of the National Professional Council of Cardiology (CNPC) (2012)
- President of the French Society of Cardiology (2012-) & Vice-President (2010-2011), General Secretary (2008-2009), Scientific Secretary (2004-2008) & Member of the board of the French Society of Cardiology (2000-)

B. Grant supports

- *Non-invasive studies of myocardial infarction*: Lavoisier Grant, French Ministry of Health (1986); Squibb Laboratory (1987); Fédération de Cardiologie d'Ile de France (1988)
- *Phenotype-genotype correlations in familial HCM* – French Society of Cardiology (1995)
- *Cell therapy in murine cardiomyopathies* – European Society of Cardiology (1996)
- *Three-dimensional echocardiography of the mitral valve* – Cino Del Duca (1996)
- *Myocardial effects of the kallikrein-kinin system in murine models* – GIP-Aventis/INSERM (2001)
- *Cardiac Progenitors Transatlantic Alliance* – CaPTAA Transatlantic Leducq Network (Associate member - 2005-2010)
- *Cell therapy for ischemic MR* – NIH R21 HL723 Grant (2002-2005) ;

- *Myoblast transplantation in ischemic cardiomyopathy* – AP/HP & French Ministry of Health – Phase I National clinical study (Co-PI) (1999-2001) & Phase II International clinical study (MAGIC Study, Co-PI and Director of the international Echocardiographic Core laboratory) (2001-2007)
- *PHRC - Clinical study of autologous myoblast transplantation in post-infarction ischemic heart failure (Co-Investigator)*: Assistance Publique-Hôpitaux de Paris, French Ministry of Health (Phase I 1999-2001 & Phase II 2001-2007)
- *Mitral Valve Disease: From Genetic Mechanisms to Improved Repair* – MITRAL Transatlantic Leducq Network (European Coordinator, 2007-2012)
- *Cell Therapy in Cardiac and Vascular Diseases* – French Ministry of Research (GIS “Cell-CV”) (Director, 2007-2011)
- *INTENSE, Initiative Nationale Technologique d'Envergure pour une NeuroStimulation Evoluée*, Pôle de compétitivité OSEO-Programme Innovation Stratégique Industrielle –Ministère de l'Enseignement Supérieur et de la Recherche (Partenaire, 2012-2016)

c. Selected peer-reviewed publications (chronological order)

1. Does karate injure blood vessels of the hand? M Vayssairat, P Priollet, A Hagège, L Capron, E Housset. **Lancet** 1984;1:529-30
2. Optimal spatio-temporal Fourier filtration for noise reduction of echocardiographic endocardial borders. JD Thomas, A Hagège, JB Newell, CY Choong, G Wilkins, AE Weyman. **Computers Cardiol** 1987;9:78-81
3. Improved accuracy of echocardiographic endocardial borders by spatiotemporal filtered fourier reconstruction: description of the method and optimisation of filters cutoffs. JD Thomas, A Hagège, CY Choong, G Wilkins, JB Newell, AE Weyman. **Circulation** 1988;77:415-28
4. Three-dimensional echocardiographic reconstruction of the mitral valve with implications for the diagnosis of mitral valve prolapse. RA Levine, MD Handschumacher, A Hagège, P Harrigan, J Marshall, AE Weyman. **Circulation** 1989;80:589-98
5. Long-term efficacy of dynamic cardiomyoplasty: clinical, ultrasonic and hemodynamic evidence in one case. A Hagège, M Desnos, J Baragan, C Guerot, JC Chachques, A Carpentier. **Eur Heart J** 1990;11:662-5
6. Long term evaluation of dynamic cardiomyoplasty: preliminary results. A Hagège, M Desnos, JC Chachques, A Carpentier, F Fernandez, F Fontaliran, C Guerot. **Lancet** 1990;335:1122-4
7. Mapping of a novel gene for familial hypertrophic cardiomyopathy to chromosome 11. L Carrier, C Henstenberger, J Beckman, P Guicheney, C Dufour, J Bercovici, E Dausse, I Berrebi-Bertrand, C Wisniewsky, D Pulvenis, L Fetler, A Vignal, J Weissenbach, D Hillaire, J Feingold, JB Bouhour, A Hagège, M Desnos, R Isnard, O Dubourg, M Komajda, K Schwartz. **Nature (Genetics)** 1993;4:311-4
8. Familial Hypertrophic cardiomyopathy: microsatellite haplotyping and identification of a hot-spot for mutations in the b-myosin heavy chain gene. E Dausse, M Komajda, L Fetler, O Dubourg, C Dufour, L Carrier, C Winewsky, J Bercovici, C Hengstenberg, S Al-Mahdawi, R Isnard, A. Hagège, JB Bouhour, M Desnos, J Beckman, J Weissenbach, K Schwartz, P Guicheney. **J Clin Invest** 1993;92:2807-13
9. Determination of left ventricular mass with electron beam computed tomography in deformed, hypertrophic human hearts. E Mousseaux, F Beygui, P Fornès, G Chatelier, A Hagège, M Desnos, D Lecompte, JC Gaux. **Eur Heart J** 1994;15:832-41
10. Doppler echocardiography in familial hypertrophic cardiomyopathy: The French Cooperative Study. O Dubourg, R Isnard, A Hagège, L Fetler, P Messner-Pellenc, M Desnos, A Millaire, A Sacrez, JB Bouhour, M Laurent, K Schwartz, M Komajda. **Echocardiography** 1995;12:235-41
11. Clinical study of the efficacy of latissimus dorsi muscle flap stimulation after cardiomyoplasty. A Hagège, M Desnos, F Fernandez, B Besse, N Mirochnik, F Castaldo, JC Chachques, A Carpentier, C Guérot. **Circulation** 1995;92:II210-5
12. Crochetage (notch) in the R wave in inferior limb leads: a new independent electrocardiographic hallmark of atrial septal defect. J Heller, A Hagège, B Besse, M desnos, FN Marié, C Guérot. **J Am Coll Cardiol** 1996;27:877-82
13. The codon 102 of the cardiac troponin T gene is a putative hot spot for mutations in familial hypertrophic cardiomyopathy. F Forissier, L Carrier, H Farza, G Bonne, J Bercovici, P Richard, B Hainque, PJ Townsend, MH Yacoub, S Fauré, O Dubourg, A Millaire, AA Hagège, M Desnos, M Komajda, K Schwartz. **Circulation** 1996;94:3069-73.
14. Eight-year human dynamic cardiomyoplasty: preserved structure of myofibres and vessels of the latissimus dorsi. U Carrara, JC Chachques, M Desnos, A Hagège, F Fontaliran, A Carpentier. **Basic Applied Myol** 1996;6:333-6
15. Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. L Carrier, G Bonne, E Bährend, B Yu, P Richard, F Niel, B Hainque, C Cruaud, F Gary, S Labeit, JB Bouhour, O Dubourg, M Desnos, A Hagege, RJ Trent, M Komajda, M Fiszman, K Schwartz. **Circ Res** 1997;80:427-34
16. Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population. P Charron, O Dubourg, M Desnos, R Isnard, A Hagège, A Millaire, L Carrier, G Bonne, F Tesson, P Richard, JB Bouhour, K Schwartz, M Komajda. **Circulation** 1997;96:214-9
17. Does transplantation of cardiomyocytes improve function of infarcted myocardium ? M Scorsin, A Hagège, F Marotte, N Mirochnik, H Copin, M Barnoux, A Sabri, JL Samuel, L Rappaport, P Menasché. **Circulation** 1997;96:II188-93

18. Genotype-phenotype correlations in familial hypertrophic cardiomyopathy: a comparison between mutations in the cardiac protein C and the B-myosin heavy chain genes. Ph Charron, O Dubourg, M Desnos, R Isnard, A Hagege, G Bonne, L Carrier, F Tesson, JB Bouhour, JC Buzzi, J Feingold, K Schwartz, M Komajada. **Eur Heart J** 1998;19:139-45
19. Familial hypertrophic cardiomyopathy: cardiac ultrasonic abnormalities in genetically affected subjects without echocardiographic evidence of left ventricular hypertrophy. A Hagege, O Dubourg, M Desnos, N Mirochnik, R Isnard, G Bonne, L Carrier, JB Bouhour, K Schwartz, M Komajda. **Eur Heart J** 1998;19:490-9
20. Routine three dimensional echocardiography: A utopian dream or a tool for the future ? A Hagege, N Mirochnik, M Desnos, H Neamatalla, E Messas, O Clément, C Guérot. **J Noninvasive Cardiol** 1998;II:12-9
21. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin binding protein C gene. Ph Charron, O Dubourg, M Desnos, M Bennaceur, L Carrier, AC Camproux, R Isnard, A Hagege, JM Langlard, G Bonne, P Richard, B Hainque, JB Bouhour, K Schwartz, M Komajada. **Circulation** 1998;97:2230-6
22. Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped children. Ph Charron, O Dubourg, M Desnos, JB Bouhour, R Isnard, A Hagege, L Carrier, G Bonne, F Tesson, P Richard, B Hainque, K Schwartz, M Komajda. **Eur Heart J** 1998;19:1377-82
23. Can cellular transplantation improve function in doxorubicin-induced heart failure ? M Scorsin, A Hagege, I Dolizy, N Mirochnik, F Marotte, M Le Bert, JL Samuel, L Rappaport, P Menasche. **Circulation** 1998;97:II-117-28
24. Genotype-phenotype analysis in four families with mutations in B-myosin heavy chain gene responsible for familial hypertrophic cardiomyopathy.: report of new mutations. F Tesson, P Richard, P Charron, B Mathieu, C Cruaud, L Carrier, O Dubourg, N Lautié, M Desnos, A Millaire, R Isnard, A Hagege, JB Bouhour, M Bennaceur, B Hainque, P Guicheney, K Schwartz, M Komajda. **Human Mutation** 1998;12:385-92
25. Gene delivery to the myocardium by intrapericardial injection. Y Fromes, A Salmon, X Wang, H Collin, A Rouche, A Hagege, K Schwartz, MY Fiszman. **Gene therapy** 1999;6:683-8
26. Double heterozygosity for mutations in the B-myosin heavy chain gene and in the cardiac myosin binding protein C gene in a family with hypertrophic cardiomyopathy. P Richard, R Isnard, L Carrier, O Dubourg, Y Donatien, B Mathieu, G Bonne, F Gary, P Charron, A Hagege, M Komajda, K Schwartz, B Hainque. **J Med Genet** 1999;36:542-5
27. Adenoviral cardiostrophin 1 gene transfer protects PMN mice from progressive motor neuropathy. T Bordet, H Schmalbruch, B Pettmann, A Hagege, L Castelnau-Patkine, A Kahn, G Haase. **J Clin Invest** 1999;104:1077-85
28. Comparison of the effects of fetal cardiomyocytes and skeletal myoblasts transplantation on post-infarct left ventricular function. M Scorsin, A Hagege, JT Vilquin, M Fiszman, F Marotte, JL Samuel, L Rappaport, K Schwartz, P Menasche. **J Thor Cardiovasc Surg** 2000;119:1169-75
29. Intramyocardial transplantation of autologous myoblasts : can tissue processing be optimized? B Pouzet, JT Vilquin, A Hagege, M Scorsin, E Messas, M Fiszman, K Schwartz, P Menasché. **Circulation** 2000;102:III-210-5
30. Cardiac functional improvement by a human Bcl2 transgene in a mouse model of ischemia/reperfusion injury. V Brocheriou, A Hagege, A Oubenaissa, M Lambert, M Duriez, M Wassef, S Akli, A Kahn, P Menasché, H Gilgenkranz. **J Gene Med** 2000;2:326-33
31. Cellular cardiomyoplasty : a new hope in heart failure. A Hagege, P Menasché. **Heart** 2000;84:465-6
32. Myoblast transplantation for heart failure P. Menasché, A. Hagege, M. Scorsin, B. Pouzet, M. Desnos, D. Duboc, K. Schwartz, JT Vilquin, JP Marolleau. **Lancet** 2001;357:279-80
33. Tissue kallikrein is required for normal cardiac function in the mouse. P Meneton, M Bloch-Faure, A Hagege, H Ruetten, W Huang, S Bergaya, D Ceiler, D Gehring, I Martins, G Salmon, CM Boulanger, J Nüssberger, B Crozatier, JM Gasc, D Heudes, P Bruneval, T Doetschman, J Ménard, F Alhenc-Gelas. **P Natl Acad Sci USA** 2001;98:2634-9
34. Renin-angiotensin system contribution to cardiac hypertrophy in experimental hyperthyroidism : an echocardiographic study. A Basset, J Blanc, E Messas, A Hagege, JL Elghozi. **J Cardiovasc Pharmacol** 2001;37:163-72
35. Factors affecting functional outcome following autologous skeletal myoblast transplantation. B Pouzet, JT Vilquin, A Hagege, M Scorsin, K Schwartz, P Menasché. **Ann Thor Surg** 2001;71:844-51
36. Is skeletal myoblast transplantation clinically relevant in the era of angiotensin-converting enzyme inhibitors ? B Pouzet, S Ghostine, JT Vilquin, I Garcin, M Scorsin, A Hagege, D Duboc, K Schwartz, P Menasché. **Circulation** 2001;104:1223-8
37. Angiotensin-converting enzyme inhibitor therapy improves respiratory muscle strength in patients with heart failure. Coirault C, Hagege A, Chemla D, Fratacci MD, Guerot C, Lecarpentier Y. **Chest**. 2001;119:1755-60.
38. Regeneration of the myocardium : A new role in the treatment of ischemic heart failure ? Hagege A, Vilquin JT, Bruneval P, Menasché P. **Hypertension** 2001;38:1413-5
39. Chronic V2 vasopressin receptor stimulation increases basal blood pressure and exacerbates deoxyxorticosterone acetate-salt hypertension. N Fernandez, P Bruneval, A Hagege, D Heudes, S Ghostine, N Bouby. **Endocrinology** 2002;143:2759-66
40. Long-term efficacy of myoblast transplantation on regional structure and function after myocardial infarction. S Ghostine, C Carrion, LC Guarita Souza, P Richard, P Bruneval, JT Vilquin, B Pouzet, K Schwartz, P Menasché, A Hagege. **Circulation**. 2002;106:I-131-6
41. Survival, haemodynamics and cardiac remodelling follow up in mice after myocardial infarction. Pons S, Fornes P, Hagege A, Heudes D, Giudicelli JF, Richer C. **Clin Exp Pharmacol Physiol**. 2003;30:25-31
42. Cardiovascular phenotypes of kinin B2 receptor- and tissue kallikrein-deficient mice. Trabold F, Pons S, Hagege AA, Bloch-Faure M, Alhenc-Gelas F, Giudicelli JF, Richer-Giudicelli C, Meneton P. **Hypertension**. 2002;40:90-5.

43. Relation between QT duration and maximal wall thickness in familial hypertrophic cardiomyopathy. Jouven X, Hagege A, Charron P, Carrier L, Dubourg O, Langlard JM, Aliaga S, Bouhour JB, Schwartz K, Desnos M, Komajda M. *Heart* 2002;88:153-7
44. Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol. Jourdain P, Funck F, Fulla Y, Hagege A, Bellorini M, Guillard N, Loiret J, Thebault B, Desnos M. *Eur J Heart Fail* 2002;4:269-76
45. Autologous myoblast grafting in ischemic cardiomyopathy: Clinical validation of long-term cell viability and differentiation. A Hagege, C Carrion, JT Vilquin, P Menasché, D Duboc, JP Marolleau, Michel Desnos, Patrick Bruneval. *Lancet* 2003;361:491-2
46. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. P Menasché, A Hagege, JT Vilquin, M Desnos, E Abergel, B Pouzet, A Bel, S Sarateanu, M Scorsin, K Schwartz, P Bruneval, M Benbunan, JP Marolleau, D Duboc. *J Am Coll Cardiol* 2003; 41:1078-83
47. Long-term (1 year) functional and histological results of autologous skeletal muscle cells transplantation in rat. Al Attar N, Carrion C, Ghostine S, Garcin I, Vilquin JT, Hagege AA, Menasche P. *Cardiovasc Res* 2003;58:142-8
48. Effects of Angiotensin II Type 1 Receptor Blockade in ApoE-Deficient Mice with Post-Ischemic Heart Failure. Pons S, Hagege A, Fornes P, Gervais M, Giudicelli JF, Richer C. *J Cardiovasc Pharmacol* 2003;42:17-23
49. Accuracy of European diagnostic criteria for familial hypertrophic cardiomyopathy in a genotyped population. Charron P, Forissier JF, Amara ME, Dubourg O, Desnos M, Bouhour JB, Isnard R, Hagege A, Benaiche A, Richard P, Schwartz K, Komajda M. *Int J Cardiol.* 2003;90:33-38
50. Transplantation of autologous fresh bone marrow into infarcted myocardium: a word of caution. Bel A, Messas E, Agbulut O, Richard P, Samuel JL, Bruneval P, Hagege AA, Menasche P. *Circulation.* 2003;108 Suppl 1:II247-52.
51. Efficacy of chordal cutting to relieve chronic persistent ischemic mitral regurgitation. Messas E, Pouzet B, Touchot B, Guerrero JL, Vlahakes GJ, Desnos M, Menasche P, Hagege A, Levine RA. *Circulation.* 2003;108 Suppl 1:II111-5.
52. Recommendations of the French Society of Cardiology concerning indications for doppler echocardiography. Cohen A, Abergel E, Blanchard B, Chauvel C, Habib G, Hagege A, Isnard R, Lardoux H, Roudaut R, Wolf JE. *Arch Mal Coeur Vaiss.* 2003;96(3):223-63.
53. Temporal patterns of bone marrow cell differentiation following transplantation in doxorubicin-induced cardiomyopathy. Agbulut O, Menot ML, Li Z, Marotte F, Paulin D, Hagege AA, Chomienne C, Samuel JL, Menasche P. *Cardiovasc Res.* 2003;58(2):451-9.
54. Serial left ventricular adaptations in world-class professional cyclists: implications for disease screening and follow-up. Abergel E, Chatellier G, Hagege AA, Oblak A, Linhart A, Ducardonnet A, Menard J. *J Am Coll Cardiol.* 2004;44(1):144-9.
55. Comparison of human skeletal myoblasts and bone marrow-derived CD133+ progenitors for the repair of infarcted myocardium. Agbulut O, Vandervelde S, Al Attar N, Larghero J, Ghostine S, Leobon B, Robidel E, Borsani P, Le Lorc'h M, Bissery A, Chomienne C, Bruneval P, Marolleau JP, Vilquin JT, Hagege A, Samuel JL, Menasche P. *J Am Coll Cardiol.* 2004;44(2):458-63.
56. Does the functional efficacy of skeletal myoblast transplantation extend to nonischemic cardiomyopathy? Pouly J, Hagege AA, Vilquin JT, Bissery A, Rouche A, Bruneval P, Duboc D, Desnos M, Fiszman M, Fromes Y, Menasche P. *Circulation.* 2004;110(12):1626-31.
57. Use of skeletal myoblasts for the treatment of patients with cardiomyopathy Menasché Ph, Desnos M, Hagege AA. In : Braunwald's Heart Disease, 7th edition Online
58. Patterns of cell death and proliferation after skeletal myoblast transplantation in infarcted rat myocardium. Maurel M, Azarnoush K, Sabbah L, Vignier N, Le Lorc'h M, Mandet C, Bissery A, Garcin I, Carrion C, Fiszman M, Bruneval P, Hagege AA, Carpentier A, Vilquin JT, Menasché Ph. *Transplantation* 2005;80: 660-65.
59. Percutaneous transluminal septal coil embolisation as an alternative to alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Lafont A, Durand E, Brasselet C, Mousseaux E, Hagege A, Desnos M. *Heart.* 2005;91(1):92.
60. Skeletal myoblast transplantation through a catheter-based coronary sinus approach: an effective means of improving function of infarcted myocardium. Brasselet C, Morichetti MC, Messas E, Carrion C, Bissery A, Bruneval P, Vilquin JT, Lafont A, Hagege AA, Menasche P, Desnos M. *Eur Heart J.* 2005 Aug;26(15):1551-6.
61. Mediastinitis due to Mycobacterium tuberculosis after a redo open heart surgery. Achouh P, Aoun N, Hagege A, Fabiani JN. *J Cardiovasc Surg.* 2005;46(1):93-4.
62. Diagnostic accuracy of a 2D left ventricle hypertrophy score for familial hypertrophic cardiomyopathy. Forissier JF, Charron P, Tezenas du Montcel S, Hagege A, Isnard R, Carrier L, Richard P, Desnos M, Bouhour JB, Schwartz K, Komajda M, Dubourg O. *Eur Heart J.* 2005;26(18):1882-6.
63. Detection of pathologic or physiologic left ventricular remodeling in athletes. Abergel E, Hagege AA. *J Am Coll Cardiol.* 2005 May 17;45(10):1731
64. Myoblast transplantation for heart failure: where are we heading? Alfieri O, Livi U, Martinelli L, Arpesella G, Valfre C, Lapenna E, Desnos M, Hagege AA, Menasche P. *Ital Heart J.* 2005;6(4):284-8.
65. Enhancement of the functional benefits of skeletal myoblast transplantation by means of coadministration of hypoxia-inducible factor 1alpha. Azarnoush K, Maurel A, Sabbah L, Carrion C, Bissery A, Mandet C, Pouly J, Bruneval P, Hagege AA, Menasche P. *J Thorac Cardiovasc Surg.* 2005;130(1):173-9.
66. Effect of aldosterone in tissue kallikrein deficient mice. Picard N, Sabbah L, Hagege A, Bruneval P, Alhenc-Gelas F. *Hypertension.* 2005;23(8):A7-8.
67. Roncalli J, Leobon B, Massabuau P, Galinier M, Parini A, Pathak A, Bourin P, Hagege AA, Menasche P, Fournial G, Fauvel JM. Cardiac cellular therapy: from cells to the first clinical uses. *Arch Mal Coeur Vaiss.* 2005;98(6):637-48.

68. Myoblast transplantation for heart failure: where are we heading? Menasche P, Hagege AA, Desnos M. *Arch Mal Coeur Vaiss*. 2005;98(6):649-54.
69. Transplantation of cardiac-committed mouse embryonic stem cells to infarcted sheep myocardium: a preclinical study. Menard C, Hagege AA, Agbulut O, Barro M, Morichetti MC, Brasselet C, Bel A, Messas E, Bissery A, Bruneval P, Desnos M, Puceat M, Menasche P. *Lancet*. 2005;366(9490):1005-12.
70. Can cold or heat shock improve skeletal myoblast engraftment in infarcted myocardium? Maurel A, Azarnoush K, Sabbah L, Vignier N, Le Lorc'h M, Mandet C, Bissery A, Garcin I, Carrion C, Fiszman M, Bruneval P, Hagege A, Carpentier A, Vilquin JT, Menasche P. *Transplantation*. 2005;80(5):660-5.
71. Fabry disease and hypertrophic cardiomyopathy. Hagege AA. *Med Sci (Paris)*. 2005;21:33-6.
72. Routine delivery of myoblasts during coronary artery bypass surgery: why not? Menasche P, Desnos M, Hagege AA. *Nat Clin Pract Cardiovasc Med*. 2006;3(S1):S90-S93.
73. Can bone marrow-derived multipotent adult progenitor cells regenerate infarcted myocardium? Agbulut O, Mazo M, Bressolle C, Gutierrez M, Azarnoush K, Sabbah L, Niederlander N, Abizanda G, Andreu EJ, Pelacho B, Gavira JJ, Perez-Ilzarbe M, Peyrard S, Bruneval P, Samuel JL, Soriano-Navarro M, Garcia-Verdugo JM, Hagege AA, Prosper F, Menasche P. *Cardiovasc Res*. 2006;21.
74. Chordal cutting does not adversely affect left ventricle contractile function. Messas E, Yosefy C, Chaput M, Guerrero JL, Sullivan S, Menasche P, Carpentier A, Desnos M, Hagege AA, Vlahakes GJ, Levine RA. *Circulation*. 2006 Jul 4;114(1 Suppl):1524-8.
75. Cardiomyopathy and sport. Hagege A. *Arch Mal Coeur Vaiss*. 2006 Nov;99(11):1007-10.
76. Skeletal myoblast transplantation in ischemic heart failure: long-term follow-up of the first phase I cohort of patients. Hagege AA, Marolleau JP, Vilquin JT, Alheritiere A, Peyrard S, Duboc D, Abergel E, Messas E, Mousseaux E, Schwartz K, Desnos M, Menasche P. *Circulation*. 2006;114(1 Suppl):I108-13.
77. Autologous myoblast transplantation for chronic ischemic mitral regurgitation. Messas E, Bel A, Morichetti MC, Carrion C, Handschumacher MD, Peyrard S, Vilquin JT, Desnos M, Bruneval P, Carpentier A, Menasche P, Levine RA, Hagege AA. *J Am Coll Cardiol*. 2006;47:2086-93.
78. Mice chronically fed a westernized experimental diet as a model of obesity, metabolic syndrome and osteoporosis. Demigne C, Bloch-Faure M, Picard N, Sabboh H, Besson C, Remesy C, Geoffroy V, Gaston AT, Nicoletti A, Hagege A, Menard J, Meneton P. *Eur J Nutr*. 2006;45:298-306.
79. GFP expression in muscle cells impairs actin-myosin interactions: implications for cell therapy. Agbulut O, Coirault C, Niederlander N, Huet A, Vicart P, Hagege A, Puceat M, Menasche P. *Nat Methods*. 2006;3:331.
80. Diagnostic value of a two-dimensional echocardiographic score for left ventricular hypertrophy validated by the Imatron CT scan in familial hypertrophic cardiomyopathy. Forissier JF, Charron P, du Montcel ST, Hagege A, Richard P, Desnos M, Schwartz K, Mousseaux E, Komajda M, Dubourg O. *Arch Mal Coeur Vaiss*. 2006;99:877-82.
81. Routine delivery of myoblasts during coronary artery bypass surgery: why not? Menasché Ph, Desnos M, Hagege AA. *Nature Clin Practice Cardiovasc Med* 2006;3 (suppl 1):90-3.
82. Inherited metabolic cardiomyopathies. Germain DP, Linhart A, Desnos M, Hagege AA. *Presse Med* 2007;36:1S48-54.
83. Differentiation in vivo of cardiac committed human embryonic stem cells in post-myocardial infarcted rats. Tomescot A, Leschik J, Bellamy V, Dubois G, Messas E, Bruneval P, Desnos M, Hagege AA, Amit M, Itskovitz J, Menasché P, Pucéat M. *Stem Cells*. 2007;25:2200-5.
84. Can erythropoietin improve skeletal myoblast engraftment in infarcted myocardium? Chanséaume S, Azarnoush K, Maurel A, Bellamy V, Peyrard S, Bruneval P, Hagege AA, Menasché P. *Interact Cardiovasc Thorac Surg*. 2007;6:293-7.
85. Is xenotransplantation of embryonic stem cells a realistic option? Bonnevie L, Bel A, Sabbah L, Al Attar N, Pradeau P, Weill B, Le Deist F, Bellamy V, Peyrard S, Ménard C, Desnos M, Bruneval P, Binder P, Hagege AA, Pucéat M, Menasché P. *Transplantation*. 2007;83:333-5.
86. Green fluorescent protein impairs actin-myosin interactions by binding to the actin-binding site of myosin. Agbulut O, Huet A, Niederländer N, Puceat M, Menasché P, Coirault C. *J Biol Chem*. 2007;282:10465-71.
87. Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy: early and 6 months follow-up. Durand E, Mousseaux E, Coste P, Pillière R, Dubourg O, Trinquart L, Chatellier G, Hagege A, Desnos M, Lafont A. *Eur Heart J*. 2008;29:348-55.
88. Management of the patient with chronic coronary artery disease. Hagege AA. *Rev Prat*. 2008;58:1541-8.
89. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial. First randomized placebo-controlled study of myoblast transplantation. Menasché P, Alfieri O, Janssens S, McKenna W, Reichenspurner H, Trinquart L, Vilquin JT, Marolleau JP, Seymour B, Larghero J, Lake S, Chatellier G, Solomon S, Desnos M, Hagege AA. *Circulation*. 2008;117:1189-200.
90. Self-assembling peptide nanofibers and skeletal myoblast transplantation in infarcted myocardium. Dubois G, Segers VF, Bellamy V, Sabbah L, Peyrard S, Bruneval P, Hagege AA, Lee RT, Menasché P. *J Biomed Mater Res B Appl Biomater*. 2008;87:222-8.
91. Tissue kallikrein deficiency aggravates cardiac remodelling and decreases survival after myocardial infarction in mice. Pons S, Griol-Charhbil V, Heymes J, Fornes P, Heudes D, Hagege A, Loyer X, Meneton P, Giudicelli JF, Samuel JL, Alhenc-Gelas F, Richer C. *Eur J Heart Fail*. 2008;10:343-51.
92. Pericardial effusion causing echocardiographic mimicking of left intra-atrial thrombus. Messas E, Szymanski C, Fabiani JN, Desnos M, Hagege A. *Eur J Echocardiogr*. 2009;10:353-5.
93. Characterization of the paracrine effects of human skeletal myoblasts transplanted in infarcted myocardium. Perez-Ilzarbe M, Agbulut O, Pelacho B, Ciorba C, San Jose-Eneriz E, Desnos M, Hagege AA, Aranda P, Andreu EJ, Menasché P, Prosper F. *Eur J Heart Fail*. 2008; 10: 1065-72.

94. Genetic mechanisms of mitral valve prolapse. Slaugenhaupt S, Levine R, Hagege A, Jeunemaitre X, Le Marec H, Schott JJ, Probst V. **Curr Cardiovasc Risk Rep.** 2008;2(6):463-467.
95. Can Mesenchymal Stem Cells Induce Tolerance to Cotransplanted Human Embryonic Stem Cells? Puymirat E, Geha R, Tomescot A, Bellamy V, Larghero J, Trinquart L, Bruneval P, Desnos M, Hagege A, Pucéat M, Menasché P. **Mol Ther.** 2009;17:176-82.
96. New trends in treatment of hypertrophic cardiomyopathy. Hagege AA, Desnos M. **Arch Cardiovasc Dis.** 2009;102:441-7.
97. First evaluation using a validated scale of the risk of congestive heart failure among hypertensive patients treated by general practitioners (O-PREDICT survey). Hagege AA, Demil N, Errieau G, Aupetit JF, Dievert F, Mourad JJ. **Arch Cardiovasc Dis.** 2010;103:176-83.
98. Initial results of posterior leaflet extension for severe type IIIb ischemic mitral regurgitation. Messas E, Hagege AA, Emmerich J. *Circulation.* 2010;121:e36 (letter).
99. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. Blin G, Nury D, Stefanovic S, Neri T, Guillevic O, Brinon B, Bellamy V, Rücker-Martin C, Barbry P, Bel A, Bruneval P, Cowan C, Pouly J, Mitalipov S, Gouadon E, Binder P, Hagege A, Desnos M, Renaud JF, Menasché P, Pucéat M. **J Clin Invest.** 2010;120:1125-39.
100. Expression of the familial cardiac valvular dystrophy gene, filamin-A, during heart morphogenesis. Norris RA, Moreno-Rodriguez R, Wessels A, Merot J, Bruneval P, Chester AH, Yacoub MH, Hagege A, Slaugenhaupt SA, Aikawa E, Schott JJ, Lardeux A, Harris BS, Williams LK, Richards A, Levine RA, Markwald RR. **Dev Dyn.** 2010;239:2118-27.
101. Composite cell sheets: a further step toward safe and effective myocardial regeneration by cardiac progenitors derived from embryonic stem cells. Bel A, Planat-Bernard V, Saito A, Bonnevie L, Bellamy V, Sabbah L, Bellabas L, Brinon B, Vanneaux V, Pradeau P, Peyrard S, Larghero J, Pouly J, Binder P, Garcia S, Shimizu T, Sawa Y, Okano T, Bruneval P, Desnos M, Hagege AA, Casteilla L, Pucéat M, Menasché P. **Circulation.** 2010;122:S118-23.
102. Relief of mitral leaflet tethering following chronic myocardial infarction by chordal cutting diminishes left ventricular remodeling. Messas E, Bel A, Szymanski C, Cohen I, Touchot B, Handschumacher MD, Desnos M, Carpentier A, Menasché P, Hagege AA, Levine RA. **Circ Cardiovasc Imaging.** 2010;3:679-86.
103. Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study. Hagege AA, Caudron E, Damy T, Roudaut R, Millaire A, Etchecopar-Chevreuil C, Tran TC, Jabbour F, Boucly C, Prognon P, Charron P, Germain DP; on behalf of the FOCUS study investigators. **Heart.** 2011;97:131-6
104. In vivo quantitative mapping of myocardial stiffening and transmural anisotropy during the cardiac cycle. Couade M, Pernot M, Messas E, Bel A, Ba M, Hagege AA, Fink M, Tanter M. **IEEE** 2011;30:295-305.
105. Can magnetic targeting of magnetically labeled circulating cells optimize intramyocardial cell retention? Chauderge A, Wilhelm C, Chen-Tournoux A, Farahmand P, Bellamy V, Autret G, Ménager C, Hagege A, Larghero J, Gazeau F, Clément O, Menasché Ph. **Cell Transplant** 2011 Nov 11 (in press)
106. Epicardial adipose stem cell sheets results in greater post-infarction survival than intramyocardial injections. Hamdi H, Planat-Benard V, Bel A, Puymirat E, Geha R, Pidial L, Nematalla H, Bellamy V, Bouaziz P, Peyrard S, Casteilla L, Bruneval P, Hagege AA, Agbulut O, Menasché P. **Cardiovasc Res.** 2011;91:483-91.
107. Therapeutic education in patients with chronic heart failure: proposal for a multiprofessional structured programme, by a French Task Force under the auspices of the French Society of Cardiology. Jourdain P, Juillié Y; Steering and Working Group Committee Members of the French Task Force on Therapeutic Education in Heart Failure. **Arch Cardiovasc Dis.** 2011;104:189-201.
108. Mapping Myocardial Fiber Orientation using Echocardiography-Based Shear Wave Imaging. Lee WN, Pernot M, Couade M, Messas E, Bruneval P, Bel A, Hagege A, Fink M, Tanter M. **IEEE Trans Med Imaging.** 2011 Oct 19 (in press).
109. Consequences of mitral valve prolapse on chordal tension: Ex vivo and in vivo studies in large animal models. Granier M, Jensen MO, Honge JL, Bel A, Menasché P, Nielsen SL, Carpentier A, Levine RA, Hagege AA. **J Thorac Cardiovasc Surg.** 2011;142:1585-7.
110. Translational research on the mitral valve: from developmental mechanisms to new therapies. Judge DP, Markwald RR, Hagege AA, Levine RA. **J Cardiovasc Transl Res.** 2011;4:699-701.
111. The mitral valve in hypertrophic cardiomyopathy : old versus new concepts. Hagege AA, Bruneval P, Levine RA, Desnos M, Neamatalla H, Judge DP. **J Cardiovasc Transl Res.** 2011;4:757-66.
112. Ultrafast imaging of the arterial pulse wave. M. Couade, M. Pernot, E. Messas, J. Emmeriche, A. Hagege, M. Fink, M. Tanter. **IRBM** 32 (2011) 106–108
113. Mapping myocardial fiber orientation using echocardiography-based shear wave imaging. Lee WN, Pernot M, Couade M, Messas E, Bruneval P, Bel A, Hagege AA, Fink M, Tanter M. **IEEE Trans Med Imaging.** 2012;31:554-62
114. Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Selton-Suty C, Célard M, Le Moing V, Doco-Lecompte T, Chirouze C, Iung B, Strady C, Revest M, Vandenesch F, Bouvet A, Delahaye F, Alla F, Duval X, Hoen B; AEPEI Study Group. **Clin Infect Dis.** 2012;54:1230-9.
115. Can Magnetic Targeting of Magnetically Labeled Circulating Cells Optimize Intramyocardial Cell Retention? Chauderge A, Wilhelm C, Chen-Tournoux A, Farahmand P, Bellamy V, Autret G, Ménager C, Hagege A, Larghero J, Gazeau F, Clément O, Menasché P. **Cell Transplant.** 2011 (in press)
116. Atrioventricular valve development: New perspectives on an old theme. de Vlaming A, Sauls K, Hajdu Z, Visconti RP, Mehesz AN, Levine RA, Slaugenhaupt SA, Hagege A, Chester AH, Markwald RR, Norris RA. **Differentiation.** 2012;84:103-16.

117. Comprehensive Annular and Subvalvular Repair of Chronic Ischemic MR Improves Long-Term Results with Least Ventricular Remodeling. Szymanski C, Bel A, Cohen I, Touchot B, Handschumacher MD, Desnos M, Carpentier A, Menasché P, Hagège AA, Levine RA, Messas E. **Circulation**. 2012 (in press)

D. Scientific books

1. Atlas of Three-Dimensional Echocardiography, NC Nanda & VL Sorell Eds. New York, **Futura Publishing 2002**.
2. Cœur et alcool. In : Cœur et médecine interne. A Cohen & N Belmatoug Eds. Paris, **Estem 2002**.
3. Genetic basis and genotype-phenotype relationships in familial hypertrophic cardiomyopathy. In Hypertrophic Cardiomyopathy. BJ Maron Ed. New-York, **Blackwell Futura Publishing 2004**.
4. Cardiomyopathie hypertrophique, Maladies du Myocarde. In : Traité de Cardiologie. Société Française de Cardiologie Ed. Paris, **Masson 2007**.
5. Cardiomyopathies hypertrophiques. In : Maladies du myocarde, Cardiologie et maladies vasculaires. Société Française de Cardiologie Ed. **Elsevier Masson 2007**.
6. Echocardiographie tridimensionnelle. In : Imagerie du cœur et des artères coronaires. O Vignaux Ed. Médecine-Sciences, Paris, **Flammarion 2008**.
7. Cell therapy in cardiovascular diseases. Menasché,P, Hagege A, Desnos M. **Braunwald Heart Diseases** electronic Edition, 2008
8. Cardiomyopathie hypertrophique. In : Manuel d'échocardiographie clinique. A Cohen & P Gueret Eds. Médecine Sciences Publications, Paris, **Lavoisier 2012**.
9. Cardiomyopathie hypertrophique. In : Encyclopédie Médico-Chirurgicale Cardiologie. Paris, **Elsevier Masson Ed. 2012**.